Premium
Differences in cell lineage involvement between MDS‐AML and de novo AML studied by fluorescence in situ hybridization in combination with morphology
Author(s) -
Bernell Per,
Arvidsson Ingrid,
Hast Robert,
Jacobsson Björn,
Stenke Leif
Publication year - 1997
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.1997.tb01661.x
Subject(s) - clone (java method) , fluorescence in situ hybridization , biology , myeloid , bone marrow , karyotype , somatic evolution in cancer , cancer research , myelodysplastic syndromes , microbiology and biotechnology , immunology , genetics , chromosome , gene
We have employed fluorescence in situ hybridization (FISH) in combination with standard morphology (MGG/FISH) to identify the clonal involvement of different bone marrow cell lineages in 20 AML patients (14 MDS‐AML, 6 de novo AML). Even though the number of cells belonging to the abnormal clone varied between individual cases, the percentage of clonal blasts was similar in MDS‐AML and de novo AML patients. The erythropoietic cells appeared to be part of the abnormal clone in 13 of 14 patients with MDS‐AML, but only in 1 of 6 with de novo AML. Similarly, clonal granulocytes were detected in 13 of 14 patients with MDS‐AML, compared to 2 of 6 with de novo AML. Lymphocytes consistently displayed normal, diploid karyotype. The results suggest that it is possible to distinguish between MDS‐AML and de novo AML by the use of MGG/FISH; in de novo AML the abnormal chromosomal clone is generally confined to the immature myeloid cells, while in MDS‐AML mature granulocytes and erythroid cells are of clonal origin. It is, however, not possible to conclude that MDS‐AML is a “multipotent” type of leukaemia, since it cannot be ruled out that the chromosomally aberrant erythroid cells and granulocytes represent surviving cells from the original MDS clone